Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand –foot syndrome: a newly recognized toxicity
We describe cutaneous SCC of the plantar foot in two patients exposed to high doses of PLD. A 50-year-old man with angiosarcoma received a total PLD dose of 1350 mg/m2 and developed cutaneous SCC of bilateral plantar feet. A 45-year-old woman with cutaneous T-cell lymphoma was treated with a total PLD dose of 1142 mg/m2 with subsequent diagnosis of cutaneous SCC of the right plantar foot. No risk factors for SCC of the plantar foot were identified in either patient. Cutaneous SCC is likely an unreported side effect of prolonged exposure to PLD. An extended duration of hand –foot syndrome from other anti-cancer drugs may also share this risk. Regular complete skin examination with early intervention for suspicious lesions is indicated in this patient population.
Publication date: Available online 24 September 2020Source: Journal of Theoretical BiologyAuthor(s): Roberta Coletti, Andrea Pugliese, Luca Marchetti
Publication date: Available online 24 September 2020Source: Advances in Biological RegulationAuthor(s): Nilufar Rahimova, Mariana Cooke, Suli Zhang, Martin J. Baker, Marcelo G. Kazanietz
Publication date: Available online 24 September 2020Source: Biochimica et Biophysica Acta (BBA) - BiomembranesAuthor(s): Aurélie H. Benfield, Sira Defaus, Nicole Lawrence, Stephanie Chaousis, Nicholas Condon, Olivier Cheneval, Yen-Hua Huang, Lai Yue Chan, David Andreu, David J. Craik, Sónia Troeira Henriques
Publication date: Available online 24 September 2020Source: Journal of Photochemistry and Photobiology B: BiologyAuthor(s): Keisuke Nakamura, Midori Shirato, Shunichi Shishido, Yoshimi Niwano, Taro Kanno, Keiichi Sasaki, Peter Lingström, Ulf Örtengren
Abstract Endometrial cancer (EC) harboring heterozygous POLE proofreading inactivating mutations (POLE-exo*) is associated with an increased number of somatic mutations that result in a distinctive anti-tumor immune response. However, the consequences of such POLE mutations in the context of the missing wild-type allele have not yet been described in endometrial tumors. A 72-year-old woman harboring a germline monoallelic frameshift mutation (p.Pro269fsTer26) in POLE was diagnosed with an EC having a somatic heterozygous mutation in the exonuclease domain of POLE (S459F). Targeted gene sequencing revealed an ultramutated p...
CONCLUSION: The study identified both a high prevalence of xerostomia regardless of the chemotherapy used and the need to create protocols to improve the quality of life of these patients. PMID: 32965427 [PubMed - in process]
Publication date: November 2020Source: Urology Case Reports, Volume 33Author(s): Shoaib Safiullah, Shivesh Kabra, Taha Anwar, Maryna Vazmitsel, Katsiaryna Laziuk, Naveen Pokala
Publication date: Available online 25 September 2020Source: Actas Urológicas Españolas (English Edition)Author(s): L. Polanco Pujol, F. Herranz Amo, J. Caño Velasco, M. Moralejo Garate, D. Subirá Rios, G. Barbas Bernardos, J. Mayor de Castro, J. Aragón Chamizo, A. Husilllos Alonso, C. Hernández Fernández
Publication date: Available online 24 September 2020Source: European UrologyAuthor(s): Vignesh T. Packiam, Bimal Bhindi
Publication date: Available online 24 September 2020Source: European UrologyAuthor(s): Marcus Cumberbatch, Benjamin Condon, Nathan Lawrentschuk, Declan G. Murphy